Warp speed isn’t fast enough: the need for variant-proof therapeutics

Broad-spectrum vaccines and therapies are needed to get ahead of the next pandemic, and stay ahead of viral variants

Autonomous Therapeutics CEO, Ariel Weinberger, is a keynote panelist on pandemic preparedness at World Vaccine and Immunotherapy Conference / World Antiviral Congress

Autonomous Therapeutics CEO, Ariel Weinberger, is a keynote panelist on pandemic preparedness at World Vaccine and Immunotherapy Conference / World Antiviral Congress

“Rockville, Maryland’s Autonomous Therapeutics (Autonomous) is a rapidly expanding biotech developing the next generation of antivirals and therapeutics. Founded four years ago in New York City by University of Maryland alum and Harvard-trained scientist, Ariel Weinberger, the company has expanded into an 18,000 square foot facility in Rockville […}”

“A New York City antiviral drug company that’s working on therapeutics for Covid-19 and other respiratory viruses is moving its headquarters to Rockville. Autonomous Therapeutics Inc. CEO Dr. Ariel Weinberger said Thursday the company is making the move to be closer to agencies such as the National Institutes of Health, Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA) — as well as funders. The company signed a lease for 17,700 square feet at 1530 E. Jefferson St., just off Rockville Pike. Terms were not disclosed.”

“BARDA is pleased to announce the presenters for 2020 BARDA Industry Day Lightning Talks. We are in our third year of hosting Lighting Talks, as a means to incorporate our stakeholders into the Industry Day program and help companies network among our audience of top industry experts, government partners and BARDA team.”

“Blue Knight is a joint initiative between Johnson & Johnson Innovation – JLABS
and the Biomedical Advanced Research and Development Authority (BARDA) that aims to stimulate and accelerate innovation to improve global health security”

“DARPA has selected five teams of researchers to support PREventing EMerging Pathogenic Threats (PREEMPT), a 3.5-year program first announced in January 2018 to reinforce traditional medical preparedness by containing viral infectious diseases in animal reservoirs and insect vectors before they can threaten humans.”